Lumbosacral Radiculoplexus Neuropathy After COVID-19.
Journal
The neurologist
ISSN: 2331-2637
Titre abrégé: Neurologist
Pays: United States
ID NLM: 9503763
Informations de publication
Date de publication:
01 Jul 2023
01 Jul 2023
Historique:
medline:
10
7
2023
pubmed:
3
2
2023
entrez:
2
2
2023
Statut:
epublish
Résumé
Lumbosacral Radiculoplexus Neuropathy (LRPN) is a subacute, painful, paralytic, asymmetric immune-mediated lower-limb neuropathy associated with weight loss and diabetes mellitus (called DLRPN). Approximately one-third of LRPN cases have a trigger. Our purpose is to show that COVID-19 can trigger LRPN. We describe the clinical, neurophysiological, radiologic, and pathologic findings of a 55-year-old man who developed DLRPN after severe acute respiratory syndrome coronavirus-2 infection. Shortly after mild coronavirus disease 2019 (COVID-19), the patient developed severe neuropathic pain (allodynia), postural orthostasis, fatigue, weight loss, and weakness of bilateral lower extremities requiring wheelchair assistance. One month after COVID-19, he was diagnosed with type 2 diabetes mellitus. Neurological examination showed bilateral severe proximal and distal lower extremity weakness, absent tendon reflexes, and pan-modality sensation loss. Electrophysiology demonstrated an asymmetric axonal lumbosacral and thoracic radiculoplexus neuropathies. Magnetic resonance imaging showed enlargement and T2 hyperintensity of the lumbosacral plexus. Cerebral spinal fluid (CSF) showed an elevated protein (138 mg/dL). Right sural nerve biopsy was diagnostic of nerve microvasculitis. He was diagnosed with DLRPN and treated with intravenous methylprednisolone 1 g weekly for 12 weeks. The patient had marked improvement in pain, weakness, and lightheadedness and at the 3-month follow-up was walking unassisted. COVID-19 can trigger postinfectious inflammatory neuropathies including LRPN.
Identifiants
pubmed: 36728648
doi: 10.1097/NRL.0000000000000481
pii: 00127893-990000000-00052
doi:
Substances chimiques
Methylprednisolone
X4W7ZR7023
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
273-276Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Dyck PJB, Windebank AJ. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment. Muscle Nerve. 2002;25:477–491.
Dyck PJB, Engelstad J, Norell J, et al. Microvasculitis in non-diabetic lumbosacral radiculoplexus neuropathy (LSRPN): similarity to the diabetic variety (DLSRPN). J Neuropathol Exp Neurol. 2000;59:525–538.
Pinto MV, Ng PS, Dyck P, et al. Triggers and risk factors in lumbosacral radiculoplexus neuropathy (4926). Neurology. 2020;94:4926.
Suh J, Amato AA. Neuromuscular complications of coronavirus disease-19. Curr Opin Neurol. 2021;34:669–674.
Staff NP, Engelstad J, Klein CJ, et al. Post-surgical inflammatory neuropathy. Brain. 2010;133:2866–2880.
Gwathmey KG, Smith AG. Immune-mediated neuropathies. Neurol Clin. 2020;38:711–735.
Pinto MV, Ng PS, Howe BM, et al. Lumbosacral radiculoplexus neuropathy: neurologic outcomes and survival in a population-based study. Neurology. 2021;96:e2098–e2108.
Pinto MV, Ng P-S, Laughlin RS, et al. Risk factors for lumbosacral radiculoplexus neuropathy. Muscle Nerve. 2022;65:593–598.
Dyck PJB, O’brien PC, Bosch EP, et al. The multi-center double-blind controlled trial of IV methylprednisolone in diabetic lumbosacral radiculoplexus neuropathy: S27.005. Neurology. 2006;66(suppl 2):A191.
Thaisetthawatkul P, Dyck PJB. Treatment of diabetic and nondiabetic lumbosacral radiculoplexus neuropathy. Curr Treat Options Neurol. 2010;12:95–99.
Carberry N, Badu H, Ulane CM, et al. Mononeuropathy multiplex after COVID-19. J Clin Neuromuscul Dis. 2021;23:24–30.
Needham E, Newcombe V, Michell A, et al. Mononeuritis multiplex: an unexpectedly frequent feature of severe COVID-19. J Neurol. 2021;268:2685–2689.
Fargeot G, Périllaud-Dubois C, Deback C, et al. Parvovirus B19-related peripheral nerve necrotizing vasculitis following SARS-CoV-2 infection. Rev Neurol (Paris). 2022;178:158–160.